MADISON, N.J., July 27 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE)
announced today that the jury in the case of Rhonda Istnick and Henry Clepper
v. Wyeth, et al. rendered its decision, finding in favor of the Company in the
case brought by Ms. Istnick, while awarding Mr. Clepper compensatory damages
in the amount of $48,000. A third plaintiff had voluntarily dismissed her
lawsuit prior to the start of the trial.
The verdict came at the end of the first phase of a bifurcated (two phase)
trial that began on July 19, 2004 before Judge Gary S. Glazer in the Courts of
Common Pleas of the First Judicial District of Pennsylvania. Both plaintiffs
alleged heart valve injury from the use of the diet drug Pondimin. The jury's
verdict with regard to Ms. Istnick has ended that case and the parties have
resolved Mr. Clepper's claim.
The first phase sought to determine whether the plaintiffs were injured as
the result of Pondimin, and if so the amount of the damages. The second phase
would have determined liability.
Wyeth reaffirms its belief that there are a significant number of
down-stream opt out cases that lack merit and the Company will continue to
challenge them as appropriate.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and nonprescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
SOURCE Wyeth
 back to top
Related links:
http://www.wyeth.com
CONTACT:
Media - Lowell Weiner of Wyeth,
+1-973-660-5013, or Douglas Petkus of Wyeth Pharmaceuticals,
+1-484-865-5140; or Investor - Justin Victoria of Wyeth,
+1-973-660-5340
|
